Published in Aliment Pharmacol Ther on January 01, 2002
Meta-analysis of the placebo response in ulcerative colitis. Dig Dis Sci (2007) 0.86
Venous thromboembolism with inflammatory bowel disease. World J Gastroenterol (2008) 0.85
Thromboxane-prostanoid receptor expression and antagonism in dextran-sodium sulfate-induced colitis. Inflamm Res (2010) 0.78
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 28.24
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med (1997) 10.67
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis (2000) 6.90
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21
Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 3.85
Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci U S A (1998) 2.88
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis (2001) 2.80
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med (2000) 2.78
Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology (1989) 2.66
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 2.62
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis (1999) 2.55
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol (2001) 2.39
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 2.23
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 2.21
Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology (1999) 2.15
Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther (2013) 2.12
Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology (1993) 2.03
Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol (1999) 1.90
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology (1999) 1.84
Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther (2005) 1.79
American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12. Gastroenterology (1998) 1.71
Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol (1993) 1.70
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology (2001) 1.57
Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther (1995) 1.40
Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severity. Gastroenterology (2000) 1.40
The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol (1998) 1.35
Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program. Dig Dis Sci (1989) 1.34
Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut (1997) 1.32
A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol (2000) 1.31
Prevalence and incidence of inflammatory bowel disease in family members. Gastroenterology (1986) 1.26
Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery. Anesthesiology (1993) 1.25
Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther (2003) 1.20
Clostridium difficile culture-positive toxin-negative diarrhea. Am J Gastroenterol (1986) 1.20
Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf (2000) 1.15
Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol (2000) 1.14
Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol (2000) 1.14
Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther (1998) 1.11
Colon cancer surveillance in chronic ulcerative colitis: historical cohort study. Am J Gastroenterol (1990) 1.11
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther (2010) 1.07
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology (1999) 1.05
Passive smoking is associated with an increased risk of developing inflammatory bowel disease in children. Am J Gastroenterol (1993) 1.04
Disseminated Trichosporon beigelii (cutaneum). Cancer (1981) 1.02
Cigarette smoking in Crohn's disease. Am J Gastroenterol (1989) 1.01
Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci (1990) 1.01
Optimal timing of colonoscopy to screen for cancer in ulcerative colitis. Ann Intern Med (1988) 1.01
Use of high density cultures of Escherichia coli for high level production of recombinant Pseudomonas aeruginosa exotoxin A. Appl Microbiol Biotechnol (1991) 0.99
Testing nicotine gum for ulcerative colitis patients. Experience with single-patient trials. Dig Dis Sci (1990) 0.99
Infectious complications associated with hairy cell leukemia. J Infect Dis (1981) 0.98
Side-to-side isoperistaltic strictureplasty in extensive Crohn's disease: a prospective longitudinal study. Ann Surg (2000) 0.97
Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol (2000) 0.97
Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial. J Card Fail (1997) 0.97
Linkage and linkage disequilibrium in chromosome band 1p36 in American Chaldeans with inflammatory bowel disease. Hum Mol Genet (2000) 0.97
A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis (1999) 0.96
Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Aliment Pharmacol Ther (2013) 0.95
Circulating lymphocyte subpopulations in Crohn's disease. Gastroenterology (1983) 0.94
Confirmation of a susceptibility locus for Crohn's disease on chromosome 16. Inflamm Bowel Dis (1997) 0.92
Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens (1997) 0.89
Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology (1997) 0.88
Lack of association between oral contraceptive use and Crohn's disease: a community-based matched case-control study. Gastroenterology (1989) 0.88
Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am (1999) 0.88
Wasp venom proteins: phospholipase A1 and B. Arch Biochem Biophys (1984) 0.88
Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther (2003) 0.87
Cigarette smoking and ulcerative colitis: a case-control study. Mayo Clin Proc (1994) 0.87
Antigenic cross-reactivity of venom proteins from hornets, wasps, and yellow jackets. J Allergy Clin Immunol (1985) 0.87
Calcium channels in smooth muscle. Properties and regulation. Ann N Y Acad Sci (1989) 0.87
Effects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic function: comparison with D-L-nebivolol and atenolol. J Cardiovasc Pharmacol (1993) 0.87
Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid. Gastroenterology (1988) 0.86
Pattern and prognosis of liver function test abnormalities during parenteral nutrition in inflammatory bowel disease. Hepatology (1985) 0.86
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther (2011) 0.86
Preoperative total parenteral nutrition for bowel resection in Crohn's disease. Dig Dis Sci (1989) 0.85
Acute leukemia following inflammatory bowel disease. Dig Dis Sci (1982) 0.84
Lack of association between oral contraceptive use and ulcerative colitis. Gastroenterology (1990) 0.84
Melittin-specific monoclonal and polyclonal IgE and IgG1 antibodies from mice. J Immunol (1984) 0.83
A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia. Neurogastroenterol Motil (2009) 0.82
Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin. Dis Colon Rectum (1995) 0.81
Protein-losing enteropathy and massive pulmonary embolism in a patient with giant inflammatory polyposis and quiescent ulcerative colitis. Am J Med (1996) 0.81
Crohn's disease. Curr Probl Surg (1993) 0.81
Survival of small bowel transplants in canine mixed hematopoietic chimeras: preliminary results. Transplant Proc (2002) 0.81
Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther (2001) 0.81
Medium-term effects of beta-blockade on left ventricular mechanics: a double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. J Card Fail (1996) 0.80
Pharmacologic and radioligand binding analysis of the actions of 1,4-dihydropyridine activators related to Bay K 8644 in smooth muscle, cardiac muscle and neuronal preparations. Naunyn Schmiedebergs Arch Pharmacol (1989) 0.78
Smoking and inflammatory bowel disease in families. Am J Gastroenterol (1988) 0.78
Pneumocystis carinii pneumonia during cyclosporine therapy for ulcerative colitis. N Engl J Med (1992) 0.78
Duration of recurrent ileitis after ileocolonic resection correlates with presurgical extent of Crohn's disease. Gut (1995) 0.78
Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther (2004) 0.78
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther (2005) 0.78
Medical therapy to reduce postoperative Crohn's disease recurrence. Am J Gastroenterol (2000) 0.77
European evidence-based consensus on the diagnosis and management of Crohn's disease. Gut (2007) 0.76
Administration of nebivolol after coronary artery bypass in patients with altered left ventricular function. J Cardiovasc Pharmacol (1993) 0.76
Nicotine for colitis--the smoke has not yet cleared. N Engl J Med (1994) 0.76
Acute pancreatitis associated with high-concentration lipid emulsion during total parenteral nutrition therapy for Crohn's disease. Gastroenterology (1986) 0.76
Medical management of Crohn's disease. Drugs Today (Barc) (1998) 0.76
pANCA and classification resistance in ulcerative colitis. Mayo Clin Proc (1996) 0.75
Protection from primary sclerosing cholangitis: smoke trails of just coattails? Gastroenterology (1996) 0.75
Surveying surveillance: are gastroenterologists consistently inconsistent, inconsistently consistent, or poorly educated? Gastrointest Endosc (2000) 0.75
Surveillance colonoscopy in ulcerative colitis: is the message loud and clear? Am J Gastroenterol (1995) 0.75
Commentary: pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther (2012) 0.75
Review article: the medical management of Crohn's disease. Aliment Pharmacol Ther (1996) 0.75
A registry of clinical trials. Inflamm Bowel Dis (1996) 0.75